RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs. OBJECTIVES: To develop a predictive score for LC risk for patients with COPD. METHODS: The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD LC screening score (COPD-LUCSS) to be validated in P-IELCAP. MEASUREMENTS AND MAIN RESULTS: By regression analysis, age greater than 60, body mass index less than 25 kg/m(2), pack-years history greater than 60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS, which ranges from 0 to 10 points. Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison with low-risk patients, in both cohorts LC risk increased 3.5-fold in the high-risk category. CONCLUSIONS: The COPD-LUCSS is a good predictor of LC risk in patients with COPD participating in LC screening programs. Validation in two different populations adds strength to the findings.
RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) are at high risk for lung cancer (LC) and represent a potential target to improve the diagnostic yield of screening programs. OBJECTIVES: To develop a predictive score for LC risk for patients with COPD. METHODS: The Pamplona International Early Lung Cancer Detection Program (P-IELCAP) and the Pittsburgh Lung Screening Study (PLuSS) databases were analyzed. Only patients with COPD on spirometry were included. By logistic regression we determined which factors were independently associated with LC in PLuSS and developed a COPD LC screening score (COPD-LUCSS) to be validated in P-IELCAP. MEASUREMENTS AND MAIN RESULTS: By regression analysis, age greater than 60, body mass index less than 25 kg/m(2), pack-years history greater than 60, and emphysema presence were independently associated with LC diagnosis and integrated into the COPD-LUCSS, which ranges from 0 to 10 points. Two COPD-LUCSS risk categories were proposed: low risk (scores 0-6) and high risk (scores 7-10). In comparison with low-risk patients, in both cohorts LC risk increased 3.5-fold in the high-risk category. CONCLUSIONS: The COPD-LUCSS is a good predictor of LC risk in patients with COPD participating in LC screening programs. Validation in two different populations adds strength to the findings.
Authors: R P Young; R J Hopkins; B A Hay; M J Epton; G D Mills; P N Black; H D Gardner; R Sullivan; G D Gamble Journal: Postgrad Med J Date: 2009-10 Impact factor: 2.401
Authors: Juan P de Torres; Gorka Bastarrika; Juan P Wisnivesky; Ana B Alcaide; Arantza Campo; Luis M Seijo; Jesús C Pueyo; Alberto Villanueva; María D Lozano; Usua Montes; Luis Montuenga; Javier J Zulueta Journal: Chest Date: 2007-12 Impact factor: 9.410
Authors: Ran You; Francesco J DeMayo; Jian Liu; Sung-Nam Cho; Bryan M Burt; Chad J Creighton; Roberto F Casal; Donald R Lazarus; Wen Lu; Hui-Ying Tung; Xiaoyi Yuan; Andrea Hill-McAlester; Myunghoo Kim; Sarah Perusich; Loraine Cornwell; Daniel Rosen; Li-Zhen Song; Silke Paust; Gretchen Diehl; David Corry; Farrah Kheradmand Journal: Cancer Immunol Res Date: 2018-04-13 Impact factor: 11.151
Authors: Barbara Bp Yawn; Byron Thomashaw; David M Mannino; MeiLan K Han; Ravi Kalhan; Stephen Rennard; Scott Cerrata; James D Crapo; Robert Wise Journal: Chronic Obstr Pulm Dis Date: 2017-07-15
Authors: Mauricio S Caetano; Huiyuan Zhang; Amber M Cumpian; Lei Gong; Nese Unver; Edwin J Ostrin; Soudabeh Daliri; Seon Hee Chang; Cesar E Ochoa; Samir Hanash; Carmen Behrens; Ignacio I Wistuba; Cinthya Sternberg; Humam Kadara; Carlos Gil Ferreira; Stephanie S Watowich; Seyed Javad Moghaddam Journal: Cancer Res Date: 2016-04-01 Impact factor: 12.701
Authors: Nasim Khosravi; Mauricio S Caetano; Amber M Cumpian; Nese Unver; Cynthia De la Garza Ramos; Oscar Noble; Soudabeh Daliri; Belinda J Hernandez; Berenice A Gutierrez; Scott E Evans; Samir Hanash; Andrei M Alekseev; Yi Yang; Seon Hee Chang; Roza Nurieva; Humam Kadara; Jichao Chen; Edwin J Ostrin; Seyed Javad Moghaddam Journal: Cancer Immunol Res Date: 2018-05-15 Impact factor: 11.151